Management of Magnesium and Parathyroid Hormone in Patients with End-Stage Renal Disease
Introduction to Magnesium and PTH Management
- The American College of Cardiology recommends maintaining PTH levels between 150-300 pg/mL to prevent adynamic bone disease and osteitis fibrosa in patients with end-stage renal disease (ESRD) 1, 2
- The National Kidney Foundation suggests targeting magnesium levels between 0.90-1.05 mmol/L to avoid the U-shaped curve of risk 1, 2
Treatment Targets and Interventions
- For PTH <150 pg/mL, reduce magnesium concentration in dialysate to 0.25-0.50 mmol/L and discontinue calcium-based phosphate binders and vitamin D therapy 2, 3
- For PTH 150-300 pg/mL, maintain magnesium dialysate concentration at 0.50-0.75 mmol/L and monitor magnesium and PTH levels regularly 1, 2, 4
- For PTH >300 pg/mL, increase magnesium concentration in dialysate to 0.75 mmol/L and consider starting or increasing vitamin D therapy 1, 4
Critical Warnings and Precautions
- Avoid using high magnesium dialysate (>0.75 mmol/L) in patients with PTH <150 pg/mL as it may worsen adynamic bone disease 2
- Monitor magnesium levels every 1-2 months in patients at risk of adynamic bone disease 2
- Adynamic bone disease increases the risk of hip fractures by 4-fold and impairs the skeleton's ability to regulate calcium and phosphorus, leading to vascular calcification 2, 5